Pure Global
NCT06302270

CFTR Modulators in Pregnancy and Postpartum

Monitoring of Women and Children Exposed to the Combination of Elexacaftor-tezacaftor-ivacaftor During Bregnancy and Through Mother's Own Milk.
Region Stockholm·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cystic Fibrosis
Study type
Observational
Sponsor & location
Primary sponsor
Region Stockholm
Location
Stockholm, Sweden
Timeline & enrollment
Phase
N/A
Start date
Mar 15, 2024
End date
Jan 31, 2039
Enrollment
75 participants
Primary outcome

Health effects in the newborn infant

Summary

Observational study on women with Cystic Fibrosis treated with CFTR modulators during
 pregnancy and postpartum and their children. Registration on maternal health parameters and
 effects of CFTR-modulators in the newborn infant as well as effects of exposure through
 mother's own milk.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06302270
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06302270 through Pure Global AI's free database. This phase not specified trial is sponsored by Region Stockholm and is currently Recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 75 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.